There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Register for Updates
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
NCT05295290
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who: 1. Are age \<21 years. 2. Have presentation to participating medical center with evaluation in Emergency Room and/or hospitalization. 3. Received either the 1st, 2nd, 3rd or booster dose(s) of COMIRNATY within 7 days of symptom onset. 4. Meet criteria of Centers for Disease Control and Prevention cas... Read More
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
08/04/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Myocarditis
Register for Updates
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825
Recruiting
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Site 0221 - Tufts Medical Center - PPDS, Boston, Massachusetts +1 locations
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: 84000220 - Massachusetts General Hospital, Boston, Massachusetts
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
Pilot/Pivotal Study of DBS+Rehab After Stroke
NCT05701280
Recruiting
The RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating arm weakness and reduced function after a stroke.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Stroke, Upper Extremity Paresis
Register for Updates
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250
Recruiting
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Research Site, Boston, Massachusetts
Conditions: B-cell Malignancies
Register for Updates
Wearable Evaluation of Ambulatory Readings for Blood Pressure
NCT06610448
Recruiting
The purpose of this project is to compare the performance and validity of novel wearable technologies that measure blood pressure (BP) and physical activity with a Spacelabs Ambulatory Blood Pressure Monitoring (ABPM) device.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/04/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Normal Blood Pressure, Controlled Hypertension, Uncontrolled Hypertension
Register for Updates
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810
Recruiting
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/04/2025
Locations: Research Site, Boston, Massachusetts +1 locations
Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Register for Updates
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
NCT06123338
Recruiting
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts
Conditions: Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
Register for Updates
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
NCT06533826
Recruiting
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Register for Updates
The Protrieve PROTECTOR Study
NCT06495996
Recruiting
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Venous Thromboembolism, Deep Venous Thrombosis
Register for Updates